Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Attal, 1996, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome., N Engl J Med, 335, 91, 10.1056/NEJM199607113350204 Child, 2003, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma., N Engl J Med, 348, 1875, 10.1056/NEJMoa022340 Barlogie, 1997, Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma., Blood, 89, 789, 10.1182/blood.V89.3.789 Cavo, 2007, Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study., J Clin Oncol, 25, 2434, 10.1200/JCO.2006.10.2509 van de Velde, 2007, Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma., Haematologica, 92, 1399, 10.3324/haematol.11534 Harousseau, 2009, The role of complete response in multiple myeloma., Blood, 114, 3139, 10.1182/blood-2009-03-201053 Chanan-Khan, 2010, Importance of achieving a complete response in multiple myeloma, and the impact of novel agents., J Clin Oncol, 28, 2612, 10.1200/JCO.2009.25.4250 Cavo, 2011, Inter-ational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation., Blood, 117, 6063, 10.1182/blood-2011-02-297325 Cavo, 2005, Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma., Blood, 106, 35, 10.1182/blood-2005-02-0522 Cavo, 2009, Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma., J Clin Oncol, 27, 5001, 10.1200/JCO.2009.22.7389 Lokhorst, 2010, A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma., Blood, 115, 1113, 10.1182/blood-2009-05-222539 Harousseau, 2010, Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial., J Clin Oncol, 28, 4621, 10.1200/JCO.2009.27.9158 Cavo, 2010, Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study., Lancet, 376, 2075, 10.1016/S0140-6736(10)61424-9 Rosinol, 2010, A phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib [abstract]., Blood (ASH Annual Meeting Abstracts), 116, 139 Sonneveld, 2010, HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract]., Blood (ASH Annual Meeting Abstracts), 116, 23 Moreau, 2011, Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma., Blood, 118, 5752, 10.1182/blood-2011-05-355081 Richardson, 2010, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma., Blood, 116, 679, 10.1182/blood-2010-02-268862 Barlogie, 2006, Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies., Blood, 107, 2633, 10.1182/blood-2005-10-4084 Mihelic, 2007, Maintenance therapy in multiple myeloma., Leukemia, 21, 1150, 10.1038/sj.leu.2404633 Hicks, 2008, A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma., Cancer Treat Rev, 34, 442, 10.1016/j.ctrv.2008.02.003 Attal, 2010, Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract]., Blood (ASH Annual Meeting Abstracts), 116, 141 McCarthy, 2010, Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract]., Blood (ASH Annual Meeting Abstracts), 116, 21 Palumbo, 2010, Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients., J Clin Oncol, 28, 800, 10.1200/JCO.2009.22.7561 Ladetto, 2010, Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma., J Clin Oncol, 28, 2077, 10.1200/JCO.2009.23.7172 Roussel, 2011, Bortezomib, lenalidomide, and dexamethasone (VRD) consolidation and lenalidomide maintenance in frontline multiple myeloma patients: updated results of the IFM 2008 phase II VRD intensive program [abstract]., Blood (ASH Annual Meeting Abstracts), 118, 816 Mellqvist, 2011, Improved progression free survival with bortezomib consolidation after high dose melphalan: results of a randomized phase III trial [abstract]., Haematologica, 96 Morgan, 2012, The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis., Blood, 119, 7, 10.1182/blood-2011-06-357038 Greipp, 2005, International staging system for multiple myeloma., J Clin Oncol, 23, 3412, 10.1200/JCO.2005.04.242 Blade, 1998, Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant., Br J Haematol, 102, 1115, 10.1046/j.1365-2141.1998.00930.x Richardson, 2003, A phase 2 study of bortezomib in relapsed, refractory myeloma., N Engl J Med, 348, 2609, 10.1056/NEJMoa030288 Durie, 2006, International uniform response criteria for multiple myeloma., Leukemia, 20, 1467, 10.1038/sj.leu.2404284 Avet-Loiseau, 2010, Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)., J Clin Oncol, 28, 4630, 10.1200/JCO.2010.28.3945 Neben, 2011, Bortezomib-based induction and maintenance therapy improves outcome in myeloma patients with deletion 17p: a subgroup analysis of the HOVON65/GMMG-HD4 trial [abstract]., Haematologica, 96 Barlogie, 2010, Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms., J Clin Oncol, 28, 3023, 10.1200/JCO.2009.26.4465 Moreau, 2011, Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study., Lancet Oncol, 12, 431, 10.1016/S1470-2045(11)70081-X